Accuray (ARAY)
Nasdaq Market Closed
Accuray Incorporated is a medical technology company focused on radiation oncology. The company develops, manufactures, sells, and services systems used by hospitals and cancer treatment centres to deliver external beam radiation therapy with a high degree of precision. Its products are designed to help clinicians target tumours while limiting exposure to surrounding healthy tissue, an important objective in the treatment of many cancers.
Accuray is best known for the CyberKnife platform, a robotic radiosurgery and stereotactic body radiation therapy system. CyberKnife is used to treat tumours in the brain, spine, lung, prostate, liver, pancreas, and other areas of the body. A key feature of the system is its ability to track tumour and patient movement during treatment, including movement caused by normal breathing, and adjust radiation delivery in real time. This allows clinicians to deliver high-dose radiation from many angles without requiring rigid immobilisation in many cases.
The company also offers the Radixact platform, which is built on TomoTherapy technology and is used for image-guided, intensity-modulated radiation therapy. These systems support a range of clinical workflows, from highly targeted treatments to broader radiation plans.
Accuray operates in a specialised, highly regulated segment of healthcare equipment, where adoption depends on clinical evidence, hospital capital budgets, reimbursement conditions, and long-term service relationships. Its competitive position rests on motion tracking, robotic delivery, treatment planning software, and ongoing support for installed systems. The company’s products are intended to expand treatment options for clinicians and improve precision in cancer care.
Last updated
- Market Cap
- 44.02M
- P/E
- —
- P/FCF
- —
- P/S
- 0.1
- Enterprise Value
- 151.13M
- Sector
- Health Care
- Industry
- Surgical and Medical Instruments and Apparatus
- Address
- 1240 DEMING WAY, MADISON, WI, 53717
Oncology Imaging AI: From Experimental to Fast-Scaling Market.
Robotic Radiotherapy Market Size to Reach USD 3.18 Billion by 2032; Surging Development in Technology Augment Market Expansion Globally – SNS Insider
Radiotherapy Market Size Expected to Surpass USD 14.76 Billion by 2034
AI and Robots in Surgery: 3 Stocks Positioned for the Next Medical Revolution
Medical Robots Market to Witness Massive Growth at USD 34.32 Billion by 2031 | SkyQuest Technology
Orthopedic Surgical Robot Market is Projected to Reach a Valuation of US$ 8.34 Billion at a CAGR of 13.5% by 2034 | Fact.MR Report
Medical Robotics Surgery Market to Grow at CAGR of 10.82% through 2033 - Rising Surgical Procedures & Increasing Regulatory Approvals
Accuray (ARAY), TrueNorth Unite to Aid Radiation Departments
Accuray's (ARAY) Precision TPS Gets Approved by China's NMPA
Inogen (INGN) Down 0.1% Since Last Earnings Report: Can It Rebound?
Accuray (ARAY) Up 2% Since Last Earnings Report: Can It Continue?
New Strong Sell Stocks for May 31st
New Strong Sell Stocks for May 24th
Accuray (ARAY) Q3 Earnings Lag Estimates, Gross Margin Contracts
Accuray (ARAY) Reports Q3 Loss, Lags Revenue Estimates
Inari Medical, Inc. (NARI) Reports Q1 Loss, Tops Revenue Estimates
Can the 4 Medical Device Stocks Hit Targets This Earnings Season?
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp
Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 44.02M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 151.13M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.06
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 0.1
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -19.88
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 0.35
- EPS
- -0.39
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -25.84M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -110.6%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -10.31%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 3.48
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.42
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 0.66
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.18
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 5.14M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 0.37
Income Statement
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Revenue | 104.85M | 102.24M | 93.94M | 127.54M | 113.24M |
| Gross profit | 25.29M | 24.07M | 26.55M | 38.98M | 31.63M |
| Operating income | -9.09M | -11.57M | -11.31M | 4.23M | 1.05M |
| EBITDA | -470K | -3.33M | -9.64M | 5.83M | 2.62M |
| Net income | -11.81M | -13.77M | -21.68M | 1.12M | -1.3M |
| Basic EPS | -0.09 | -0.11 | -0.18 | 0.01 | -0.01 |
| Diluted EPS | -0.09 | -0.11 | -0.18 | 0.01 | -0.01 |
Balance Sheet
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Total assets | 447.6M | 448.01M | 456.82M | 470.24M | 484.29M |
| Total liabilities | 405.9M | 394.59M | 394.95M | 389.07M | 434.71M |
| Total equity | 41.71M | 53.42M | 61.87M | 81.17M | 49.58M |
| Cash & equivalents | 38.07M | 41.3M | 63.34M | 57.42M | 77.82M |
| Current assets | 292.75M | 291.81M | 303.03M | 316.89M | 332.45M |
| Current liabilities | 205.84M | 199.44M | 194.61M | 192.58M | 203.43M |
Cash Flow
| Line Item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 |
|---|---|---|---|---|---|
| Operating cash flow | -5.6M | -15.99M | 12.18M | -9.71M | 18.06M |
| Investing cash flow | -1.51M | -5.6M | -3.82M | -3.4M | -2.43M |
| Financing cash flow | 4.11M | -282K | -475K | -5.85M | -2M |
| Change in cash | -3.43M | -22.06M | 7.79M | -18.11M | 14.86M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — ACCURAY INC | View Filing | |
| edgar index | S-8 — ACCURAY INC | View Filing | |
| edgar index | SD — ACCURAY INC | View Filing | |
| form 4 | Form 4 — Miele Paul Michael | View Filing | |
| edgar index | SCHEDULE 13D/A — ACCURAY INC | View Filing | |
| edgar index | 4 — ACCURAY INC | View Filing | |
| form 4 | Form 4 — TCW GROUP INC | View Filing | |
| form 4 | Form 4 — TCW GROUP INC | View Filing | |
| form 4 | Form 4 — TCW GROUP INC | View Filing | |
| form 4 | Form 4 — TCW GROUP INC | View Filing | |
| form 4 | Form 4 — TCW GROUP INC | View Filing | |
| form 4 | Form 4 — TCW GROUP INC | View Filing | |
| edgar index | 8-K — ACCURAY INC | View Filing | |
| edgar index | 10-Q — ACCURAY INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — ACCURAY INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — ACCURAY INC | View Filing | |
| edgar index | SCHEDULE 13D/A — ACCURAY INC | View Filing | |
| form 3 | Form 3 — TCW GROUP INC | View Filing | |
| form 3 | Form 3 — TCW GROUP INC | View Filing | |
| form 3 | Form 3 — TCW GROUP INC | View Filing | |
| form 3 | Form 3 — TCW GROUP INC | View Filing | |
| form 3 | Form 3 — TCW GROUP INC | View Filing | |
| form 3 | Form 3 — TCW GROUP INC | View Filing | |
| form 3 | Form 3 — TCW GROUP INC | View Filing | |
| form 3 | Form 3 — TCW GROUP INC | View Filing | |
| form 3 | Form 3 — TCW GROUP INC | View Filing | |
| form 3 | Form 3 — TCW GROUP INC | View Filing | |
| edgar index | 3 — ACCURAY INC | View Filing | |
| edgar index | 8-K — ACCURAY INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — ACCURAY INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ACCURAY INC | View Filing | |
| form 4 | Form 4 — Chalke Sandeep | View Filing | |
| edgar index | SCHEDULE 13G/A — ACCURAY INC | View Filing | |
| edgar index | 8-K — ACCURAY INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ACCURAY INC | View Filing | |
| form 4 | Form 4 — Peralta Leonel | View Filing | |
| form 4 | Form 4 — Peralta Leonel | View Filing | |
| form 4 | Form 4 — Peralta Leonel | View Filing | |
| edgar index | 424B3 — ACCURAY INC | View Filing | |
| edgar index | EFFECT — ACCURAY INC | View Filing | |
| edgar index | CORRESP — ACCURAY INC | View Filing | |
| edgar index | UPLOAD — ACCURAY INC | View Filing | |
| edgar index | 4 — ACCURAY INC | View Filing | |
| edgar index | 4 — ACCURAY INC | View Filing | |
| form 4 | Form 4 — MAYER STEVEN F | View Filing | |
| form 4 | Form 4 — MAYER STEVEN F | View Filing | |
| form 4 | Form 4 — MAYER STEVEN F | View Filing | |
| edgar index | S-3 — ACCURAY INC | View Filing | |
| edgar index | 10-K/A — ACCURAY INC | View Filing | |
| edgar index | 10-Q/A — ACCURAY INC | View Filing | |
| edgar index | 10-Q — ACCURAY INC | View Filing | |
| edgar index | 8-K — ACCURAY INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — ACCURAY INC | View Filing | |
| edgar index | NT 10-Q — ACCURAY INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — ACCURAY INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — ACCURAY INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G — ACCURAY INC | View Filing | |
| edgar index | 8-K — ACCURAY INC | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — ACCURAY INC | View Filing | |
| edgar index | 8-K — ACCURAY INC | View Filing | |
| form 4 | Form 4 — Scott Byron C | View Filing | |
| form 4 | Form 4 — Scott Byron C | View Filing | |
| form 4 | Form 4 — Scott Byron C | View Filing | |
| edgar index | 144 — ACCURAY INC | View Filing | |
| edgar index | 8-K — ACCURAY INC | View Filing |